The Latest Cardiac and Vascular News
New Study Shows Momentum in Establishing a Less Invasive Approach to Treat Patients with Severe Mitral Valve Disease DUBLIN, Sept. 27, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval to begin an early feasibility study (EFS) for its Intrepid™ transcatheter mitral […]
DUBLIN and SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) announced today late-breaking clinical data from the Onyx ONE Global Study, representing the first prospective, multi-center, randomized study evaluating clinical outcomes between two drug-eluting stents (DES) in nearly 2,000 high-bleeding risk (HBR) patients with one month of dual antiplatelet therapy […]
Improved Functionality Across Four Valve Sizes and Lowest Delivery Profile on the Market, the Evolut PRO+ TAVR System Launches in U.S. as TAVR Patient Population Grows DUBLIN, Sept. 23, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), a global leader in heart valve therapies, today announced U.S. Food and Drug Administration […]
IN.PACT AV Drug-Coated Balloon Shows Promise in Treating Arteriovenous Fistulae Lesions in End-Stage Renal Disease Patients DUBLIN and BARCELONA, Spain, Sept. 07, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) announced the first-ever results from the IN.PACT AV Access clinical study comparing the investigational IN.PACT™ AV™ drug-coated balloon (DCB) to percutaneous transluminal angioplasty (PTA) in patients with […]
DUBLIN, Aug. 29, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it will participate in the 14th Annual Wells Fargo Securities Healthcare Conference on Thursday, September 5, 2019, in Boston. Mike Coyle, executive vice president and president of the Cardiac and Vascular Group (CVG) […]
Revenue of $7.5 Billion Increased 1.5% Reported; Increased 3.5% Constant Currency GAAP Diluted EPS of $0.64; Non-GAAP Diluted EPS of $1.26 Company Raises FY20 EPS Guidance by 10 Cents DUBLIN, Aug. 20, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year […]
DUBLIN, Aug. 16, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval of the Evolut™ Transcatheter Aortic Valve Replacement (TAVR) system for patients with symptomatic severe native aortic stenosis who are at a low risk of surgical mortality. The low-risk patient population is […]
Newly Approved Minimally Invasive Therapy Treats Diseased Veins Using Proprietary Medical Adhesive Mumbai, Maharashtra, India: India Medtronic Private Limited, wholly owned subsidiary of Medtronic plc (NYSE: MDT), today announced the launch of the VenaSeal™ Closure System, which is a minimally invasive procedure that uses a proprietary medical adhesive to close the diseased vein […]
BRAMPTON, Ontario, July 23, 2019 (GLOBE NEWSWIRE) — Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE:MDT) — one of the world’s largest medical technology, services, and solutions company — announced today that it has been certified as a Great Place to WorkTM and has also made the list of 2019 Best […]
DUBLIN, July 08, 2019 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced two-year outcomes from the LATERAL clinical trial evaluating the use of its HeartWare™ HVAD™ System in patients who received the system via a less-invasive, thoracotomy implant approach. The HVAD System is a heart pump, called a left ventricular assist device […]
